BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
Bioline RX Ltd Ordinary shares (AMEX: BLNEF) Delayed: 0.86 --0 (-0%)
Previous Close $0.86    52 Week High $1.54 
Open $1.64    52 Week Low $1.15 
Day High $0.86    P/E N/A 
Day Low $0.86    EPS $0.00 
Volume 1,500       

BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 3.24 +0.08 (2.53%)
Previous Close $3.16    52 Week High $1.63 
Open $3.21    52 Week Low $0.71 
Day High $3.37    P/E N/A 
Day Low $3.15    EPS $0.00 
Volume 12,019       

BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 3.24 +0.08 (2.53%)
Previous Close $3.16    52 Week High $1.63 
Open $3.21    52 Week Low $0.71 
Day High $3.37    P/E N/A 
Day Low $3.15    EPS $0.00 
Volume 12,019       

BIOLINE RX SP ADR (NASDAQ: BLRX) Delayed: 3.24 +0.08 (2.53%)
Previous Close $3.16    52 Week High $1.63 
Open $3.21    52 Week Low $0.71 
Day High $3.37    P/E N/A 
Day Low $3.15    EPS $0.00 
Volume 12,019